« Biogen Idec Retools After FDA Clears Drug but Not Its Moniker | Main | The Swift Report: White House Exploring 'Rapture' Contingency Plans »

Serono Completes Patient Enrollment in Rebif(R) Versus Copaxone(R) Comparative Clinical Trial

Serono (virt-x: SEO and NYSE: SRA) announced today that patient enrollment has been completed in a multi-national Rebif(R) (interferon beta-1a) versus Copaxone(R) (glatiramer acetate) comparative clinical trial. This two-year trial is designed to compare the efficacy of the two therapies in patients with relapsing remitting multiple sclerosis (RRMS), who were previously untreated with disease modifying therapies.

More here.

January 5, 2005 in copaxone, rebif, research, worth following... | Permalink